BioCryst Shifts Strategy, Closing Discovery Center in Alabama

The strategic pivot includes a revised financial outlook, with the company lowering its adjusted operating expense projections to a range of $420 million to $440 million, down from its previous forecast of $450 million to $470 million. Management expects this reduced cost structure to persist beyond 2026, driven largely by the closure of the Birmingham facility. Despite the organizational overhaul, BioCryst reaffirmed its existing revenue guidance for the fiscal year.

Operational focus now centers on advancing Navenibart for hereditary angioedema prophylaxis and BCX17725, an inhibitor targeting Netherton syndrome. Simultaneously, the company resolved manufacturing delays for its Orladeyo oral pellets, confirming availability for early August. Investors reacted coolly to the announcement, sending shares down 3.7% to $9.57.